News & Events
Seasoned executive and life sciences investor joins as Anavo advances three potentially first-in-class phosphatase pipeline programs and achieves further validation for its drug discovery platform
anavotx.comCrawled Nov 3, 2026
Seasoned executive and life sciences investor joins as Anavo advances three potentially first-in-class phosphatase pipeline programs and achieves further validation for its drug discovery platform
Dr. Andrew Mortlock leads early-stage drug development at Astellas, overseeing Phase 1 and 2 studies across modalities like small molecules, antibodies, and gene therapies. He previously managed Phase 3 oncology projects at AstraZeneca as Global Franchise Head.
Dr. Gregg Siegal founded and leads ZoBio as CEO while also serving as an endowed professor at VU Amsterdam. He previously held a Dutch Royal Society Fellowship at Leiden University and spun out ZoBio from his lab technology in 2004.
Laboratory of Biosignaling & Therapeutics in the Department of Cellular and Molecular Medicine at KU Leuven, Belgiumy
Dr. Karl-Heinz Altmann is a full professor of pharmaceutical sciences and head of the Department of Chemistry & Applied Biosciences at ETH Zurich. He previously worked in industry for 13 years as a chemist and group leader at Ciba-Geigy and Novartis Pharma, and co-founded Tolremo Therapeutics AG in 2017.
Professor of Cancer Research Cold Spring Harbor Laboratory
UNLOCKING THE PHOSPHATASE TARGET CLASS: Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades.
UNLOCKING THE PHOSPHATASE TARGET CLASS: Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades.
Anavo Therapeutics is a company comprising of Anavo Therapeutics B.V. (Leiden) and Anavo Therapeutics GmbH (Heidelberg).
Anavo Therapeutics names **Dr. Vincent G. Brichard** as its new Chairman of the Board. The appointment follows the company’s focus on advancing its therapeutic pipeline. Brichard brings extensive leadership experience in biopharmaceuticals to the role.
Anavo Therapeutics names Dr. Edward Holson as Chief Scientific Officer and President of its US operations. Based in Boston, he will oversee research and development across both the US and Europe, combining the strengths of Anavo’s teams in key biotech hubs. The company specializes in harnessing phosphatase biology for therapeutic development.
BioLabs Heidelberg adds its first early-stage biotech tenants to its life-science community. The facility expands its network with new members while also securing a key partnership. The move strengthens Heidelberg’s position as a hub for life-science innovation and collaboration.
Anavo Therapeutics adds three oncology drug discovery experts—Karl-Heinz Altmann, Andrew Mortlock, and Gregg Siegal—to its Scientific Advisory Board. The hires bolster Anavo’s focus on oncology research and development with decades of combined experience in cancer therapeutics.
Vipergen applies its DNA-encoded library (DEL) technology to generate small-molecule drug leads for Anavo Therapeutics. The partnership targets phosphatase proteins, a class of enzymes linked to diseases like cancer. Vipergen’s high-fidelity DEL platforms enable discovery of novel compounds against Anavo’s selected discovery programs.
Anavo Therapeutics secures **EUR 20 million in seed funding** to develop a pipeline of **allosteric phosphatase modulators**. The company targets novel therapeutic approaches by leveraging its expertise in modulating phosphatase enzymes, a key area in drug discovery. This financing supports early-stage research and pipeline expansion in the biopharmaceutical sector.